Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant

This article was originally published in The Gray Sheet

Executive Summary

Firm files premarket approval application with FDA Feb. 28 for its Contak CD pulse generator and Easytrak lead for congestive heart failure. The Contak, which combines cardiac resynchronization capability with implantable defibrillation therapy, will be the first such device for CHF to be reviewed by the agency

You may also be interested in...



Medtronic MIRACLE Foreshadows Resynchronized Approach To CHF Therapy

A clear clinical benefit demonstrated by Medtronic's InSync atrial synchronous biventricular pacing system in treating congestive heart failure could give FDA the impetus to bring resynchronization therapy to panel review as early as June.

Medtronic MIRACLE Foreshadows Resynchronized Approach To CHF Therapy

A clear clinical benefit demonstrated by Medtronic's InSync atrial synchronous biventricular pacing system in treating congestive heart failure could give FDA the impetus to bring resynchronization therapy to panel review as early as June.

ICDs For Heart Failure: Technical Improvements Will Determine Uptake

FDA's decision to approve implantable defibrillators for congestive heart failure is likely to rest on reconciling its desire for mortality data, which will not be available for about two years, with quality-of-life data showing a benefit in some patients.

Related Content

UsernamePublicRestriction

Register

MT014560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel